Aureobasidium Allergy Shots: When Finding the Source Beats Starting Shots
Aureobasidium pullulans is the mold most associated with hypersensitivity pneumonitis from contaminated humidifiers, hot tubs, saunas, and HVAC systems — including an industrial outbreak of 115+ confirmed HP cases. No WHO/IUIS allergens are characterized and no SCIT evidence exists. The highest-yield intervention for Aureobasidium-driven illness is identifying and eliminating the wet indoor source, not immunotherapy.
Aureobasidium pullulans Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to aureobasidium pullulans — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of aureobasidium pullulans allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of aureobasidium pullulans immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of aureobasidium pullulans extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for aureobasidium pullulans allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing aureobasidium pullulans extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription aureobasidium pullulans immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat aureobasidium pullulans allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Aureobasidium pullulans?
The biology, taxonomy, and clinical fingerprint of Aureobasidium pullulans — the foundation of how SCIT targets it.
Aureobasidium pullulans begins as a pink yeast-like colony, darkening to black with age. Its polyextremotolerant biology allows it to colonize shower curtains, grout, window frames, and humidifier reservoirs.
- Scientific name
- Aureobasidium pullulans
- Family
- DothioraceaeDothideales order
- Type
- Black yeast — dematiaceous with phenotypic plasticity; outdoor and indoor wet-surface organism
- Native to
- Ubiquitous worldwide; initially pink then darkening to black with age on indoor surfaces including shower curtains, tile grout, caulking, humidifier reservoirs, HVAC systems
- Allergen proteins
- No WHO/IUIS-registered Aureobasidium allergens as of 2024Several high molecular weight allergens identified in atopic patients (Taylor 2006) but none individually characterized
- Particle size
- Initially yeast-like cells 2-5 µm; darkens and forms hyphae with age
- Avoidance difficulty
- Moderate
How Aureobasidium pullulans Allergy Presents
Symptoms by body system — useful for distinguishing Aureobasidium pullulans sensitivity from overlapping allergies and infections.
Respiratory
- Hypersensitivity pneumonitis — cough, dyspnea, and fever 4-8 hours after humidifier or HVAC exposure
- Allergic rhinitis in atopic sensitized individuals
- Asthma exacerbations in sensitized patients with wet-indoor exposure
- Chronic respiratory symptoms in contaminated occupational environments
Ocular
- Allergic conjunctivitis in atopic individuals
- Eye irritation from airborne particles in contaminated indoor environments
- Tearing and redness during heavy indoor aerosolization events
Dermal
- Non-specific skin reactions in sensitized individuals
- Rare subcutaneous mycosis in immunocompromised patients — not related to allergy
- Contact dermatitis from direct contact with contaminated surfaces
Systemic
- Fever, chills, myalgia in acute HP episodes (humidifier lung)
- Fatigue and malaise with chronic HP from ongoing exposure
- Weight loss with progressive chronic HP if source not removed
- Malaise correlating with exposure events in susceptible individuals
When Aureobasidium shows up on a panel and the patient mentions chronic cough, fever, and breathlessness after running their humidifier, I stop and think about hypersensitivity pneumonitis before I think about allergy shots. Cleaning or removing the contaminated humidifier — and sometimes the HVAC — is the intervention that changes outcomes for these patients. SCIT is not in that treatment pathway.
Where Aureobasidium pullulans Triggers Year-Round
Aureobasidium pullulans is a perennial trigger — exposure is constant for sensitized patients. Geographic intensity still varies by climate.
12-Month Intensity
Year-roundYear-round exposure in any home or workplace with contaminated humidifiers, HVAC, shower curtains, or window frames· Perennial indoor exposure as long as moisture sources remain colonized
US Exposure Map
0 high-intensity statesWhat Aureobasidium pullulans Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Aureobasidium pullulans has limited characterized cross-reactivity given the absence of registered IUIS allergens. Pan-fungal cross-reactivity via enolase, MnSOD, and related proteins may occur with other Dothideomycetes.
Dothideomycetes class-level pan-fungal cross-reactivity; both share indoor and outdoor colonization niches
Is SCIT Right for Your Aureobasidium pullulans Allergy?
Answer these questions to clarify whether your Aureobasidium sensitization reflects a hypersensitivity pneumonitis (HP) pattern or an atopic allergy pattern — two very different clinical situations.
Do you experience fever, chills, or worsening breathlessness 4-8 hours after running your humidifier, hot tub, or heating system?
The Aureobasidium pullulans SCIT Protocol
SCIT is NOT recommended as a primary or standard intervention for Aureobasidium pullulans sensitization. For the HP phenotype, complete antigen avoidance and corticosteroids are the evidence-based treatment. For confirmed atopic sensitization with rhinitis-asthma phenotype after source control, family-level mold mix SCIT may be considered with explicit evidence-gap acknowledgment.
If an atopic rhinitis-asthma phenotype is confirmed without HP, and source control has been optimized, family-level mold mix SCIT may be considered on a standard mold build-up schedule with a 30-minute observation period. Mold vials are kept separate from pollen vials. This is a low-evidence, clinical-judgment decision.
Maintenance injections continue monthly or every 2-4 weeks. Ongoing environmental monitoring for indoor moisture sources is concurrent throughout the maintenance period.
For the rare atopic-phenotype patient on SCIT, discontinuation follows standard mold SCIT protocols. Re-assessment of indoor moisture exposure at every visit.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Aureobasidium pullulans SCIT
No published SCIT RCT exists for Aureobasidium pullulans. For the HP phenotype, complete antigen avoidance and corticosteroids are the evidence-based primary interventions. For atopic sensitization, family-level evidence extrapolation is weak given Aureobasidium's distinct phylogenetic placement from Alternaria.
- HP: Complete antigen avoidance — symptom resolution70%Fink JN, et al. Hypersensitivity pneumonitis — diagnosis and management. Am J Respir Crit Care Med 2005;172(6):712-716.
No SCIT evidence exists for Aureobasidium pullulans. For the HP phenotype (humidifier lung), complete removal of the contaminated source is the intervention with the strongest evidence for symptom resolution — documented in the literature since the Banaszak 1970 NEJM industrial outbreak report. For atopic sensitization without HP, no comparable evidence supports SCIT over pharmacotherapy and source control.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Aureobasidium pullulans SCIT Side Effects
If SCIT were pursued for atopic Aureobasidium sensitization (a rare and evidence-poor clinical scenario), standard mold SCIT side effects would apply.
Local reactions
4 documentedSystemic reactions
4 documentedIf SCIT is pursued for atopic Aureobasidium sensitization, standard mold SCIT safety protocols apply, and Curex makes safe at-home self-administration possible: a personalized serum sterile-compounded to USP <797>, a prescribed epinephrine auto-injector confirmed on hand, and your first dose plus every dose change supervised live over Zoom by the prescribing allergist, with a brief post-injection self-observation since reactions almost always begin within the first 30 minutes. For HP (humidifier lung), SCIT is contraindicated as primary therapy.
SCIT vs Alternatives for Aureobasidium pullulans
For Aureobasidium-driven HP, antigen avoidance (source removal) and systemic corticosteroids for active disease are the primary interventions. For atopic sensitization without HP, pharmacotherapy and source control are first-line; SCIT is a distant consideration.
| Criterion | Source control + avoidanceBest | Corticosteroids (HP phenotype) | SCIT (atopic, non-HP) | Medications |
|---|---|---|---|---|
| Effectiveness | Primary treatment for HP — high effectiveness when source removed | Active HP: systemic corticosteroids plus avoidance | No RCT evidence; clinical judgment only | Symptomatic control for atopic phenotype only |
| 5-yr cost | Variable — HEPA, professional remediation if needed | $500-$2,000/yr for drug costs | $3,500-$8,000 over 5 years | $500-$2,000/yr ongoing |
| Duration | Permanent when source is eliminated | 6-12+ weeks for active HP episodes | 3-5 years | Ongoing |
| Convenience | Requires home/workplace inspection | Daily medication | Weekly then monthly clinic visits | Daily pills/sprays |
| Safety | No injection risks | Corticosteroid side effects with prolonged use | Systemic reactions <1% | Drug side effects long-term |
| Lasting effect | Permanent if exposure eliminated | Resolution if exposure eliminated | Uncertain for this organism | No lasting effect |
Source control + avoidanceBest
Corticosteroids (HP phenotype)
SCIT (atopic, non-HP)
Medications
For Aureobasidium HP (humidifier lung), source removal is the most effective intervention by far — no medication or injection replaces eliminating the contaminated source. For atopic patients without HP, standard mold allergy management applies. Once HP has been ruled out, Curex delivers at-home Aureobasidium SCIT as a self-administered weekly shot for $129/month all-inclusive — a personalized serum sterile-compounded to USP <797>, with a prescribed epinephrine auto-injector confirmed on hand and your first dose plus every dose change supervised live over Zoom; discuss with your allergist whether this is appropriate for your specific case.
What Aureobasidium pullulans SCIT Actually Costs
Curex at-home testing identifies Aureobasidium sensitization, prompting a targeted environmental review of humidifiers, HVAC, and bathroom surfaces before immunotherapy is considered. Standard allergy benefits may cover testing and pharmacotherapy; HP management may involve separate pulmonology billing codes.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
Flat monthly subscription — includes consult, prescription, and at-home dosing for sublingual immunotherapy.
See if you qualifyStop guessing about your aureobasidium pullulans allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Aureobasidium pullulans SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
Humidifier lung is a form of hypersensitivity pneumonitis — a lymphocytic alveolitis caused by repeated inhalation of antigens from a contaminated indoor moisture source. Aureobasidium pullulans is one of the best-documented causative organisms, first described in industrial settings (Banaszak 1970 NEJM), and subsequently documented in residential humidifiers, hot tubs, saunas, and HVAC systems. The clinical pattern is fever, chills, cough, dyspnea, and myalgia appearing 4-8 hours after exposure and typically resolving within 24-48 hours of avoidance. Diagnosis is confirmed by bronchoalveolar lavage showing lymphocytosis, high-resolution CT showing ground-glass opacities, and positive precipitin testing to the causative organism. Treatment is complete removal of the contaminated source plus systemic corticosteroids for active disease.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.